Following Thai adults with transthyretin amyloid heart disease over time
Tracks how transthyretin amyloid heart disease appears and changes in adults in Thailand.
Key facts
- Who runs it
- Mahidol University
- Where
- Bangkok, Chiang Mai, Khon Kaen, Pathum Thani, and Songkhla, ThailandSee the 8 sites
- Trial code
- Registry title
- Thailand ATTR-CM Registry
- Status
- Recruiting
- People taking part
- 105 people, planned
- Started
- 30 Jul 2024
- Expected to end
- 30 Jun 2030
- Type of study
- Observational
- Record updated
- 8 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in Thailand with transthyretin amyloid heart disease (ATTR-CM), with or without symptoms, who show heart involvement on tests.
- Age
- Older than 18 years (the record lists 18 Years to 100 Years).
- Sex
- All sexes can join.
- Disease stage
- Transthyretin amyloid cardiomyopathy (ATTR-CM), with or without symptoms. An echocardiogram must show left ventricle wall thickness of ≥ 12 mm.
- Biomarker or test result
- At least one positive test is needed: a bone scan (scintigraphy) with Perugini grade ≥ 2 and/or H/CL ratio > 1.5; or Perugini grade 1 plus a biopsy with Congo red stain; or abnormal cardiac MRI (CMR) plus a biopsy with Congo red stain.
Main reasons for not taking part
- Amyloidosis caused by proteins other than transthyretin (for example light chain amyloidosis)
- Secondary amyloidosis
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age > 18 years
- All patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy) who have either symptomatic or asymptomatic must have evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of ≥ 12 mm and with at least one of the following criteria:
- Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade ≥ 2 and/or H/CL (heart to contralateral lung) ratio > 1.5
- Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade 1 and positive cardiac biopsy tissue confirmed which Congo red stain ≥ 4 sites
- Positive scintigraphy by 99mTC-DPD [99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid] or 99mTC-PYP [Pyrophosphate] or 99mTC-HMDP [hydroxymethylene diphosphate] with Perugini grade 1 with positive non-cardiac biopsy tissue confirmed by Congo red stain
- Abnormalities on CMR (Cardiac MRI) [Subendocardium LGE (late gadolinium enhancement) and/or elevated native T1 value and/or increased extracellular volume (ECV > 0.4)] with positive non-cardiac and/or cardiac tissue biopsy confirmed by Congo red stain
Who cannot take part
- Diagnosed with amyloidosis caused by proteins other than transthyretin (light chain Amyloidosis, etc.)
- Diagnosed with secondary amyloidosis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in Thailand
- Faculty of Medicine at Chulalongkorn UniversityBangkok, ThailandContact: Sarinya Puwanant, MDNot yet recruiting
- Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, ThailandContact: Kanchalaporn Jirataiporn, B.N.SNot yet recruiting
- Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityBangkok, ThailandContact: Teerapat Yingchoncharoen, MDNot yet recruiting
- Phramongkutklao HospitalBangkok, ThailandContact: Hutsaya Prasitdumrong, MDNot yet recruiting
- Faculty of Medicine, Chiang Mai UniversityChiang Mai, ThailandContact: Arintaya Phrommintikul, MDNot yet recruiting
- Queen Sirikit Heart Center of The NortheastKhon Kaen, ThailandContact: Vichai Senthong, MDNot yet recruiting
- Faculty of Medicine, Thammasat UniversityPathum Thani, ThailandContact: Adisai Buakhamsri, MDNot yet recruiting
- Prince of Songkla UniversitySongkhla, ThailandContact: Thammarak Songsangjinda, MDTaking people
About the trial
What the trial wants to find out
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand.
The group in the trial
- ATTR Cardiomyopathy
Patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Thailand Transthyretin Amyloid Cardiomyopathy Registry
- Plain-language title
- Following Thai adults with transthyretin amyloid heart disease over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06338696, who can take part
- Record updated
- 8 May 2025